J 2013

Sugammadex in a parturient with myotonic dystrophy

ŠTOURAČ, Petr, Ivo KŘIKAVA, Judita SEIDLOVÁ, Eva STRAŽEVSKÁ, Martin HUSER et. al.

Basic information

Original name

Sugammadex in a parturient with myotonic dystrophy

Name in Czech

Použití sugammadexu u rodičky s myotonickou dystrofií

Authors

ŠTOURAČ, Petr (203 Czech Republic, guarantor, belonging to the institution), Ivo KŘIKAVA (203 Czech Republic, belonging to the institution), Judita SEIDLOVÁ (203 Czech Republic), Eva STRAŽEVSKÁ (203 Czech Republic, belonging to the institution), Martin HUSER (203 Czech Republic, belonging to the institution), Lukáš HRUBAN (203 Czech Republic, belonging to the institution), Petr JANKŮ (203 Czech Republic, belonging to the institution) and Roman GÁL (203 Czech Republic, belonging to the institution)

Edition

British Journal of Anaesthesia, OXFORD, Oxford University Press, 2013, 0007-0912

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30214 Obstetrics and gynaecology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 4.354

RIV identification code

RIV/00216224:14110/13:00067924

Organization unit

Faculty of Medicine

DOI

UT WoS

000316700600024

Keywords (in Czech)

sugammadex; myotonická dystrofie; císařský řez; celková anestezie

Keywords in English

sugammadex; myotonic dystrophy; Caesarean Section; General Anaesthesia

Tags

International impact, Reviewed
Změněno: 26/4/2014 11:36, Ing. Mgr. Věra Pospíšilíková

Abstract

ORIG CZ

V originále

Myotonic dystrophy is a chronic, slowly progressing, highly variable, inherited multisystemic disease. It is characterized by wasting of the muscles (muscular dystrophy), cataracts, heart conduction abnormalities, endocrine changes, slow gastric and bowel emptying, and myotonia. Patients with myotonic dystrophy show myotonic responses to succinylcholine and neostigmine, and increased sensitivity to non-depolarising muscle relaxants. We report two cases of a parturient with myotonic dystrophy scheduled for Caesarean Section under general anaesthesia, once in 2009 and once in 2011. Muscle relaxant anaesthetic management in 2009 consisted of rocuronium and waiting for spontaneous neuromuscular blockade recovery with arteficial ventilation in the intensive care unit for 2 hours and 30 minutes postoperatively. In 2011, the same patient was indicated for the selective binding agent sugammadex ( 4 mg kg-1) to actively reverse deep neuromuscular blockade at the end of surgery. Train of Four ratio 0.9 was achieved in 2 minutes. There was no exacerbation of myotonia and no recurrence of muscle relaxation perioperatively in either case. These two obstetric cases provide evidence for the benefits of sugammadex in patients with myotonic dystrophy. We also suggest that it could be used in other patients with neuromuscular diseases.

In Czech

Přinášíme dvě kazuistiky průběhu ukončení těhotenství císařským řezem u rodičky, u které byla diagnostikována Myotonia Congenita Levior. Poukazujeme zejména na rozdílný průběh zotavení z nervosvalové blokády užitím aktivní reverze nedepolarizujícího bloku sugammadexem.